BRAF and neoplasm: Among the patients with a KRAS/BRAF tumor tissue mutation, KRAS/BRAF mutations were detected in plasma cfDNA in 93% of patients with CRC‐LM compared to 20% of patients with CRC‐PM (p < 0.0001; Figure 1).